Ligelizumab for chronic spontaneous urticaria: a new star on the horizon
Prof. Marcus Maurer, Charité Universitätsmedizin Berlin, Germany
Results of a novel analysis of a previously published phase 2b trial, comparing ligelizumab with omalizumab in the treatment of chronic spontaneous urticaria (CSU), showed numerical superiority for ligelizumab in terms of speed of onset and duration of action [1,2].
Ligelizumab is a high-affinity, humanised, monoclonal, anti-IgE antibody, which has previously been assessed for treatment of patients with CSU who do not adequately respond to H1-antihistamines . The phase 2b dose-finding trial (NCT02477332) with 382 patients did not only find superiority to placebo but also to omalizumab . “In the present analysis we look at how long it takes before patients experience a beneficial response and how sustained this response is over the first 12 weeks of treatment,” Prof. Marcus Maurer (Charité Universitätsmedizin Berlin, Germany) told his audience . ...
Please login to read the full text of the article.